Date: 2011-09-05
Type of information: Development agreement
Compound: EVT 302
Company: Evotec (Germany) Roche (Switzerland)
Therapeutic area: Neurodegenerative diseases
Type agreement: development
commercialisation
Action mechanism:
Disease: Alzheimer’s disease
Details: Evotec and Roche have entered into an exclusive worldwide agreement for the development and commercialization of Evotec’s MAO-B inhibitor EVT 302 in patients with Alzheimer’s disease. Roche will initiate studies in 2012 to demonstrate proof of concept and will be responsible for all clinical development, manufacturing and commercialization activities. The compound, which will be entering clinical studies in AD, was originally licensed from Roche to Evotec in 2006, and initially developed in another indication.
Financial terms: Under the terms of the agreement, Roche will pay Evotec an upfront fee of $10 million. Evotec could receive further development and commercial milestone payments of up to $820 million as well as tiered double-digit royalties on sales.
Latest news:
